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OBJECTIVES We sought to determine the differences in coronary microvascular function between patients
with type 1 (insulin-deficient) and type 2 (insulin-resistant) diabetes mellitus (DM).
BACKGROUND Coronary vascular function is impaired in patients with DM. However, it is unclear whether
the type and/or severity of this vascular dysfunction are similar in patients with type 1 and
type 2 DM.
METHODS We studied 35 young subjects with DM (18 with type 1 and 17 with type 2), who were free
of overt cardiovascular complications, and 11 age-matched healthy controls. Positron
emission tomography imaging was used to measure myocardial blood flow (MBF) at rest,
during adenosine-induced hyperemia (reflecting primarily endothelium-independent vasodi-
lation), and in response to cold pressor test (CPT) (reflecting primarily endothelium-
dependent vasodilation).
RESULTS The two groups of diabetics were similar with respect to age and glycemic control. The
duration of diabetes was longer and high-density lipoprotein cholesterol levels were higher in
type 1 than in type 2 diabetics. Basal MBF was similar in the three groups studied. The
increase (from baseline) in MBF with adenosine was similar in the subjects with type 1 (161
 18%) and type 2 (185 19%) DM, but lower than in the controls (351 43%) (p 0.001
for the comparison with both groups of diabetics). Similarly, the increase in MBF during the
CPT was comparable in the subjects with type 1 (23  4%) and type 2 (19  3%) DM, but
lower compared with the controls (66  12%) (p  0.0001 for the comparison with both
groups of diabetics). These differences persisted after adjusting for the duration of diabetes,
insulin treatment, metabolic abnormalities, and autonomic neuropathy.
CONCLUSIONS These results demonstrate markedly reduced and similar endothelium-dependent and
-independent coronary vasodilator function in subjects with both type 1 and type 2 DM.
These results suggest a key role of chronic hyperglycemia in the pathogenesis of vascular
dysfunction in diabetes. (J Am Coll Cardiol 2003;41:1387–93) © 2003 by the American
College of Cardiology Foundation
Diabetes mellitus (DM) predisposes people to premature
atherosclerotic coronary artery disease (CAD)—the leading
cause of mortality among patients with diabetes (1). Al-
though much of the excess in CAD risk can be accounted
for by the presence of diabetes-associated coronary risk
factors such as hypertension, dyslipidemia, and obesity, a
significant proportion of it remains unexplained (2). This
suggests that other mechanisms contribute to the increased
cardiovascular risk among patients with diabetes. One such
mechanism may involve the deleterious effect of diabetes on
vascular function and in particular endothelial function,
thereby increasing the potential for coronary vasoconstric-
tion and thrombosis.
There is consistent evidence that coronary vascular func-
tion is impaired in diabetes and that this precedes clinically
overt CAD, suggesting that it may be an early marker of
atherosclerosis (3–6). Factors such as diabetes-associated
hypertension and dyslipidemia may contribute to the sever-
ity of vascular dysfunction in diabetes. However, data from
our group and others demonstrate that in diabetes coronary
vascular dysfunction is present even in subjects without
hypertension or dyslipidemia, suggesting that diabetes per
se or a constellation of factors associated with it (e.g.,
hyperglycemia and insulin resistance) may be causally re-
lated to this vascular dysfunction (5,6). Further, it remains
unclear whether coronary vascular function is equally af-
fected in patients with types 1 and 2 diabetes. Our objective
was to determine the differences in coronary microvascular
function in patients with type 1 (insulin-deficient) and type
2 (insulin-resistant) DM, and the degree to which micro-
vascular function in subjects with diabetes differs from
healthy control subjects.
METHODS
Study population. We studied 35 subjects with DM (18
with type 1 and 17 with type 2 diabetes) (age 42  7 years),
who were free of overt cardiovascular complications (age 24
to 52 years) (Table 1). Patients were classified as either type
1 or 2 DM based on standard criteria used including
C-peptide levels, age at onset of diabetes, and a history of
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ketosis (7). The average duration of diabetes for the group
was 14  12 years. Eleven age-matched subjects without
diabetes served as healthy controls. Each subject was eval-
uated with a careful history, physical examination, resting
electrocardiogram (ECG), and maximal treadmill exercise
test echocardiography. We included diabetic subjects fulfill-
ing the following inclusion criteria: 1) no clinical evidence of
heart disease (i.e., angina or heart failure symptoms); 2) a
negative maximal treadmill exercise test; 3) no ischemic
changes or left ventricular hypertrophy on resting ECG or
two-dimensional echocardiography; 4) no evidence of cere-
brovascular or peripheral vascular disease; 5) no history of
more than mild hypertension (blood pressure [BP]160/95
mm Hg); 6) no overt nephropathy (serum creatinine 1.4
mg/dl); and 7) a glycohemoglobin level 12%. Subjects
with a history of cardiomyopathy or valvular heart disease or
active smoking were excluded. Ten diabetics had evidence
of mild-to-moderate retinopathy. Eight subjects with type 2
diabetes were receiving insulin treatment. All subjects in the
study had a low probability of significant obstructive CAD
based on the absence of cardiovascular symptoms, a normal
resting and maximal exercise ECG, and echocardiography.
Study design. The Human Investigation Committee of
Wayne State University approved the study protocol, and all
participants gave written informed consent. Each subject
made two visits to the study hospital, during which time
cardiac sympathetic nerve function and myocardial blood
flow (MBF) were assessed. Cardiac sympathetic innervation
and MBF were evaluated using a whole-body positron
emission tomography (PET) (Siemens/CTI EXACT HR,
Knoxville, Tennessee).
All subjects refrained from caffeine-containing beverages
or theophylline-containing medications for 24 h before each
hospital visit. Two diabetic subjects were receiving a calcium
channel blocker for mild hypertension, and eight subjects
were receiving a low-dose angiotensin-converting enzyme
inhibitor. None of the subjects were using nitrates or
beta-blockers. These medications were discontinued 24 h
prior to PET imaging. None of the subjects received
medications known to interfere with catecholamine uptake
in presynaptic nerve terminals. All subjects were studied in
the fasted state.
PET imaging. ASSESSMENT OF CARDIAC SYMPATHETIC
NERVE TERMINALS. Cardiac sympathetic innervation was
evaluated using the norepinephrine analogue [11C]hy-
droxyephedrine (HED), as described previously (6). A
15-min transmission scan was acquired for correction of
photon attenuation. Beginning with the intravenous bolus
administration of HED (0.286 mCi/kg), serial images were
acquired for 40 min.
ASSESSMENT OF MBF. Using [13N]ammonia as the flow
tracer, MBF was measured at rest, during adenosine-
induced hyperemia, and in response to the cold pressor test
(CPT), as described previously.(6) A 15-min transmission
Table 1. Baseline Characteristics of Study Population
Variables
Type 1 Diabetics
n  18
Type 2 Diabetics
n  17
Healthy Controls
n  11
Age (yrs) 39  9 44  5 38  9
Body mass index (kg/m2) 27.2  4.5 31.9  4.4† 25.1  4.7
Duration of diabetes (yrs) 21  12‡ 6  4 —
Fasting blood glucose (mg/dl)* 191  68 195  67 83  11§
Glycohemoglobin (%)* 10.7  2.8 10.7  2.7 —
Total cholesterol (mg/dl) 189  37 189  35 158  23
HDL cholesterol (mg/dl) 52  14 39  9¶ 51  17
LDL cholesterol (mg/dl) 112  25 111  34 87  28
Cholesterol/HDL cholesterol 3.8  1.1 5.2  1.9 3.5  1.7
Triglycerides (mg/dl) 127  95 180  76 100  44
Creatinine (md/dl) 0.95  0.4 0.94  0.3 0.73  0.2
BUN (md/dl) 15  4 13  4 15  4
Urine albumin (g/mg) 40  65 32  40 9  8
vWF antigen (%) 139  53 127  35 108  39
HED retention 0.17  3 0.17  3 0.20  2
*Glycohemoglobin and fasting blood glucose values are average of four years. All p values are based on Tukey post-hoc tests. †p
 0.05 vs. type 1 diabetics and controls; ‡p  0.001 vs. type 2 diabetics; §p  0.001 vs. both groups of diabetics; ¶p  0.01
vs. type 1 diabetics and p  0.07 vs. controls; p  0.04 vs. type 1 diabetics and p  0.05 vs. controls.
BUN  blood urea nitrogen; HED  [11C] hydroxyphedrine; HDL  high-density lipoprotein; LDL  low-density
lipoprotein; vWF  von Willebrand factor.
Abbreviations and Acronyms
ANOVA  analysis of variance
BMI  body mass index
BP  blood pressure
CAD  coronary artery disease
CPT  cold pressor test
DM  diabetes mellitus
ECG  electrocardiogram
HDL  high-density lipoprotein
HED  [11C]hydroxyephedrine
MBF  myocardial blood flow
PET  positron emission tomography
ROI  regions of interest
vWF  von Willebrand factor
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scan was acquired for correction of photon attenuation.
Beginning with the intravenous bolus administration of
[13N]ammonia (0.286 mCi/kg), serial images were acquired
for 20 min. Thirty minutes later, adenosine (0.14 mg/kg/
min) was infused intravenously for 4 min. Two minutes into
the adenosine infusion, a second dose of [13N]ammonia was
injected and images were recorded in the same acquisition
sequence. Thirty minutes later, a CPT was performed by
immersing the patient’s hand and forearm in ice water
(equal parts of ice and water at 0°C to 2°C) for 2 min.
Forty-five seconds into the CPT, a third dose of [13N]am-
monia was injected and images were recorded in the same
acquisition sequence. The heart rate, systemic BP, and
12-lead ECG were recorded at baseline and throughout the
infusion of adenosine and the CPT.
DATA ANALYSIS. In order to quantify the regional myocar-
dial catecholamine storage and MBF, identical regions of
interest (ROIs) encompassing the left anterior descending,
circumflex, and right coronary artery territories were auto-
matically assigned to each of four mid-ventricular short-axis
slices of the HED and [13N]ammonia images, as previously
described (6). A small circular ROI was manually placed in
the center of the left ventricular blood pool of each image set
to obtain the arterial input function. The corresponding
ROIs were then copied to the entire HED and [13N]am-
monia image sequences, and regional myocardial tissue and
blood pool time-activity curves obtained. In each coronary
territory, the retention fraction of HED was calculated by
dividing the [11C] concentration in myocardial tissue at 12
min postinjection by the integral of the [11C] concentration
in arterial blood. Regional MBF was calculated by fitting
the [13N]ammonia time-activity curves with a three-
compartment tracer kinetic model. An index of coronary
vascular resistance was calculated by dividing the mean
aortic BP by MBF. The coronary vasodilator reserve was
defined as the ratio between hyperemic and basal MBF.
Laboratory analyses. Venous plasma and serum samples
were taken after an overnight fast. Plasma glucose was
measured by the glucose oxidase method. Serum cholesterol
and triglyceride concentrations were measured using stan-
dard enzymatic methods. High-density lipoprotein (HDL)
cholesterol was measured with the Equal HDL Direct
Method and the Technicon DAX System (Bayer, Tarry-
town, New York). Low-density lipoprotein cholesterol was
calculated using the Friedewald formula (8). The von
Willebrand factor (vWF) antigen (a marker of endothelial
cell damage) was measured by immunoelectrophoresis. Gly-
cohemoglobin level was measured by high-performance
liquid chromatography (4% to 8%).
Statistical analysis. Data are presented as mean  SD.
Baseline characteristics of patients between groups were
compared using single factor analysis of variance
(ANOVA). Significant ANOVAs were followed with
Tukey post-hoc tests to identify differences between groups.
To compare systemic hemodynamics, MBF, and myocardial
vasodilator reserve across subject groups (i.e., type 1 diabet-
ics, type 2 diabetics, and controls) and conditions (i.e.,
baseline, CPT, and hyperemia), separate 33 mixed design
ANOVAs were run where group was the between subjects
factor and condition was the repeated measures factor. For
the outcomes of systolic BP and mean aortic BP a doubly
multivariate 33 mixed design ANOVA was run due to the
high intercorrelation of these two measures. Multivariate
tests are reported for main effects and interactions involving
the repeated measures factor. When the sphericity assump-
tion was violated the Greenhouse-Geisser correction was
used for the error term and degrees of freedom for the
post-hoc tests.
To compare coronary flow reserve across the subject
groups a single factor ANOVA was performed. All signif-
icant main effects for condition were followed with Tukey
post-hoc tests to assess changes (from baseline) during the
CPT and peak hyperemia. Significant main effects for group
were followed with Tukey post-hoc tests comparing each of
the groups. Significant group by condition interactions were
followed with simple effects tests using a Tukey correction
to assess differences across the conditions within each
subject group and differences across the subject groups
within each condition (9). Independent predictors of
changes in MBF in response to adenosine and the CPT
were investigated using multiple regression analysis. For all
analyses an alpha of 0.05 was used to define statistical
significance. Values of p 0.1 also are reported as they were
taken to indicate trends toward significance.
RESULTS
Baseline characteristics. Table 1 summarizes the baseline
characteristics of the study patients. As expected, the disease
duration was longer in the subjects with type 1 than among
those with type 2 diabetes. Body mass index (BMI) was
higher in the subjects with type 2 compared with those with
type 1 diabetes and the controls. Baseline glucose was lower
in the controls as compared with both groups of diabetics.
However, glycemic control was comparable in both groups
of diabetics. Additionally, HDL cholesterol was lower and
cholesterol/HDL cholesterol ratio was higher in the subjects
with type 2 diabetes.
Systemic hemodynamics. Analyses of the systemic hemo-
dynamics revealed significant main effects by condition
(adenosine or CPT) for all measures (heart rate F[2, 42] 
218.13, p  0.001; overall systolic BP and mean aortic BP
F[4, 172]  20.35, p  0.001; and the rate-pressure
product F[2, 42]  89.44, p  0.001), and main effects by
subject group for three of the measures (systolic BP F[2, 43]
 7.94, p  0.001; mean aortic BP F[2, 43]  4.76, p 
0.014; and the rate-pressure product F[2, 43]  3.41, p 
0.042) (Table 2). Across all three conditions (baseline,
adenosine, and CPT), type 2 diabetics had significantly
higher systolic BP, mean aortic BP, and rate-pressure
product as compared with controls. Likewise, type 1 dia-
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betics had significantly higher systolic BP and marginally
higher mean aortic BP and rate-pressure product as com-
pared with controls.
Predictors of changes in MBF in response to adenosine
and the CPT. CHANGES IN MBF WITH ADENOSINE. In
univariate analysis, the vWF antigen level (R  0.34, p 
0.048) was the only significant predictor of the myocardial
vasodilator reserve, whereas HDL cholesterol (R  0.32,
p  0.057) was of borderline predictive value. We then
performed a stepwise multiple regression analysis to deter-
mine independent predictors of the changes in myocardial
vasodilator reserve. Variables considered in this analysis
included those with borderline statistical significance in the
univariate analysis and those of particular interest to this
study including diabetes type, fasting blood glucose, glyco-
hemoglobin, diabetes duration, and an interaction between
fasting blood glucose and diabetes duration. In the final
model, the only significant independent predictor of the
change in myocardial vasodilator reserve was the vWF
antigen level (R2 change  0.113, F change  4.21, p 
0.048), whereas HDL cholesterol (p 0.105), diabetes type
(p  0.265), fasting blood glucose (p  0.32), duration (p
 0.216), and the interaction between fasting blood glucose
and duration (p  0.763) were not significant predictors of
the change in myocardial vasodilator reserve.
CHANGE IN MBF IN RESPONSE TO THE CPT. In univariate
analysis, the fasting blood glucose (R  0.42, p  0.013),
the increase in heart rate (R  0.43, p  0.003), rate-
pressure product (R  0.44, p  0.003) in response to the
CPT, and the magnitude of HED retention (R 0.65, p
0.001) were the only significant predictors of the change in
MBF with the CPT, while diabetes duration (R  0.32, p
 0.060) and the glycohemoglobin level (R  0.33, p 
0.058) were of borderline predictive value. A stepwise
multiple regression analysis was also performed to deter-
mine independent predictors of the change in MBF with
the CPT. Variables considered in this analysis included
those with borderline statistical significance in the univari-
ate analysis and those of particular interest to this study
including diabetes type, fasting blood glucose, glycohemo-
globin, duration, and an interaction between fasting blood
glucose and duration. In the final model, the only significant
independent predictors of the change in MBF with to the
CPT were the fasting blood glucose (R2 change  0.08, F
change  5.6, p  0.026), duration (R2 change  0.073, F
change  4.6, p  0.039), and the magnitude of HED
retention (R2 change  0.44, F change  25.1, p  0.001).
Plasma glucose was a statistically significant predictor of the
flow response to the CPT that provided incremental infor-
mation above and beyond that provided by the HED
retention data and the duration of diabetes. The increase in
heart rate (p  0.874) and rate-pressure product (p 
0.378) with the CPT, diabetes type (p  0.298), glycohe-
moglobin (p  0.99), and the interaction between fasting
blood glucose and duration (p  0.449) were not indepen-
dent predictors of the MBF changes during the CPT.
Regional MBF and coronary vascular resistance. BASE-
LINE The baseline MBF and coronary vascular resistance
were regionally homogeneous in both groups of diabetics
and in the controls. Baseline MBF was slightly lower,
although not statistically significant, in the controls.
MBF RESPONSE TO ADENOSINE INFUSION. During hyper-
emia, MBF increased and coronary vascular resistance
decreased significantly in the three groups (Table 3). How-
ever, the increase (from baseline) in MBF with adenosine
was similar in the subjects with type 1 (161  18%) and
Table 2. Systemic Hemodynamics in the Subjects With Diabetes and in the Healthy Controls
Hemodynamic Measures
Type 1 Diabetics
n  18
Type 2 Diabetics
n  17
Healthy Controls
n  11
Heart rate (beats/min) Type 1 Type 2 Controls
Baseline 74  10 72  11 68  8
CPT* 80  10 77  12 78  16
Peak hyperemia* 100  10 98  11 99  7
Systolic BP (mm Hg) Type 1† Type 2† Controls
Baseline 127  15 129  11 111  12
CPT* 145  22 148  19 127  21
Peak hyperemia 124  15 135  22 109  13
Mean aortic BP (mm Hg) Type 1‡ Type 2† Controls
Baseline 89  9 91  8 80  6
CPT* 101  12 102  11 94  15
Peak hyperemia 84  10 90  10 79  8
Rate-pressure product Type 1‡ Type 2† Controls
Baseline 9.4  2.0 9.3  1.7 7.5  1.3
CPT* 11.6  2.3 11.5  2.7 10.1  2.9
Peak hyperemia* 12.4  2.2 13.3  3.2 10.8  1.7
All p values are based on Tukey post-hoc tests. *p  0.05 main effect of condition (CPT or peak hyperemia) vs. corresponding
value at baseline; †p  0.05 main effect of group vs. controls; ‡p  0.05 main effect of group vs. controls.
BP  blood pressure; CPT  cold pressor test.
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type 2 (185  19%) diabetes, but significantly lower than in
the controls (351  43%) (p  0.001 for the comparison
with both groups of diabetics) (Fig. 1). Consequently,
coronary vasodilator reserve was lower in the diabetics than
in the controls. These differences persisted after adjusting
for the duration of diabetes, blood glucose, BMI, insulin
treatment, and lipid profile.
MBF RESPONSE TO THE CPT. During the CPT, MBF in-
creased significantly only among controls (Table 3). The
magnitude of MBF increase was similar in the subjects with
type 1 (23  17%) and type 2 (20  13%) diabetes, but
significantly lower compared with the controls (66  39%)
(p  0.0001 for the comparison with both groups of
diabetics) (Fig. 1). The magnitude of MBF increase in
response to the CPT was also lower in the type 1 (31 4%)
and type 2 (29  3%) diabetics without evidence of cardiac
sympathetic dysfunction, as assessed by HED PET, com-
pared with the healthy controls (66 12%, p 0.01 for the
comparison with both groups of diabetics). Coronary vas-
cular resistance index fell only in the controls. These
differences persisted after adjusting for the duration of
diabetes, blood glucose, BMI, insulin treatment, lipid pro-
file, and autonomic neuropathy.
DISCUSSION
The results of this study demonstrate markedly impaired
coronary microvascular function in response to adenosine
(reflecting primarily endothelium-independent vasodila-
tion) and to the CPT (reflecting primarily endothelium-
dependent vasodilation) in young subjects with uncompli-
Table 3. MBF and Coronary Vascular Resistance in the Subjects With Diabetes and in the
Healthy Controls
Variables
Type 1 Diabetics
n  18
Type 2 Diabetics
n  17
Healthy Controls
n  11
MBF (ml/min/g)
Baseline 0.96  0.16 0.92  0.16 0.86  0.14
CPT 1.16  0.29‡ 1.10  0.24† 1.41  0.42
Peak hyperemia 2.52  0.38† 2.47  0.70*† 3.27  0.43*
Coronary flow reserve 2.47  0.51† 2.52  0.54† 3.88  0.70
Coronary vascular resistance
(mm Hg/ml/min/g)
Baseline 94  16 102  21 95  19
CPT 92  25‡ 97  20† 73  17*
Peak hyperemia 34  6*† 39  13*† 25  5*
All p values are based on simple effects tests using Tukey post-hoc tests. *p 0.01 vs. corresponding value at baseline; †p 0.05
vs. controls; ‡p  0.10 vs. controls.
CPT  cold pressor test; MBF  myocardial blood flow.
Figure 1. Percent change in myocardial blood flow in response to the infusion of adenosine and the cold pressor test in the subjects with type 1 and type 2
diabetes and in the healthy controls. All p values are based on Tukey post-hoc tests.
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cated diabetes, which confirms the results from our
laboratory and others (3–6). However, the current study is
the first to demonstrate that the kind (endothelium-
dependent and -independent) and magnitude of coronary
vascular dysfunction is similar in type 1 and type 2 diabetics,
despite their fundamental pathophysiologic and metabolic
differences. Indeed, myocardial vasodilator reserve was re-
duced by 54% and 47% in type 1 and 2 diabetics, respec-
tively, compared with controls. Likewise, the MBF response
to cold was reduced by 65% and by 71% in type 1 and type
2 diabetics, respectively, compared with controls. Impor-
tantly, the similarities in MBF between the subjects with
type 1 and type 2 diabetes persisted after adjusting for
expected baseline differences in the duration of diabetes,
BMI, insulin treatment, lipid profile, and autonomic neu-
ropathy.
Comparison with previous studies. Our findings demon-
strate striking similarities in the magnitude of sympatheti-
cally mediated coronary vasodilation between the subjects
with type 1 and type 2 diabetes. The results of multivariable
analysis assigned an important role to the degree of cardiac
sympathetic dysfunction and the duration of diabetes in
predicting the MBF response to the CPT, consistent with
previous results from our laboratory (6). Importantly,
plasma glucose was a statistically significant predictor of the
flow response to the CPT that provided incremental infor-
mation above and beyond that provided by the HED
retention data and the duration of diabetes. Furthermore,
the presence of type 1 (insulin deficiency) or type 2 (insulin
resistance) diabetes had no significant effect on the MBF
response to cold, even among those without cardiac sympa-
thetic dysfunction. Together, these findings agree and
extend previous studies in healthy volunteers (10) and in
subjects with impaired glucose tolerance (11). Williams et
al. (10) demonstrated that acute local hyperglycemia
(achieved by infusion of 50% dextrose in the brachial artery)
significantly attenuated the forearm blood flow response to
methacholine in healthy nondiabetic humans, a finding that
was independent of the systemic insulin concentration.
Kawano et al. (11) showed impaired flow-mediated brachial
artery dilation after an oral glucose loading in subjects with
normal and impaired glucose tolerance.
Diabetes-associated hypertension and dyslipidemia may
contribute to abnormalities in coronary vascular function in
diabetes. However, except for HDL cholesterol levels the
diabetic subjects in our study were matched for these
parameters. More importantly, none of the lipoprotein
fractions measured in this study were independent predic-
tors of the changes in MBF in the multivariable analysis.
Although the duration of diabetes was a marginally signif-
icant predictor of the MBF response to cold, the similarities
in MBF between subjects with type 1 and type 2 diabetes
persisted after adjusting for the duration of diabetes.
Potential mechanisms by which hyperglycemia induces
vascular dysfunction include hyperglycemia-mediated for-
mation of oxygen-derived free radicals and activation of
protein kinase C. Free radicals inactivate endothelium-
derived nitric oxide, thereby interfering with endothelium-
dependent vasodilation (12,13). Indeed, endothelial dys-
function resulting from hyperglycemia in type 1 and type 2
diabetics can be improved by the short-term administration
of the antioxidant vitamin C (14,15). Activation of protein
kinase C by hyperglycemia has also been implicated in the
development of endothelial dysfunction in diabetes, thereby
contributing to vascular dysfunction (16). Mechanisms pro-
posed to account for the effect of protein kinase C on
vascular dysfunction include the increased production of
vasoconstrictor prostanoids, changes in endothelial cell
muscarinic receptors (16), activation of nuclear factor
kappa-B with subsequent alterations in gene transcription
(17), and possibly increased formation of oxygen-derived
free radicals (16).
We also demonstrated a similar impairment of myocar-
dial vasodilator reserve in our subjects with type 1 and type
2 diabetes. One possibility is that occult atherosclerosis
might have attenuated the maximal flow response to aden-
osine. However, we deliberately studied young asymptom-
atic diabetics, all of whom had normal maximal stress
echocardiography, and none showed regional defects on
rest-stress perfusion imaging. These findings argue against
flow-limiting epicardial coronary stenoses in our diabetic
subjects (18). Although structural abnormalities in the
coronary microcirculation in the diabetics may have con-
tributed to the impaired vasodilator response to adenosine
(19), such abnormalities have not been universally observed
(20). Alternatively, the impaired vasodilator response to
adenosine in the diabetics may be related in part to the
presence of endothelial dysfunction. Although the augmen-
tation in MBF with adenosine is caused primarily by direct
interaction with A2 receptors on vascular smooth muscle
leading to direct vasodilation (a mechanism that is
endothelium-independent), a relatively small proportion of
the vasodilator response to adenosine is mediated by the
endothelial release of nitric oxide (21). The fact that the
vWF antigen level (a marker of endothelial cell damage) was
the only independent predictor of the impaired MBF
response to adenosine provides support for this hypothesis.
Nevertheless, the relatively small contribution of endothelial
function to the overall increase in MBF in response to
adenosine may explain the lack of correlation between
plasma glucose and the coronary vasodilator reserve.
Study limitations. Plasma insulin and free fatty acid levels
were not measured routinely in the diabetic subjects. Thus,
their role as possible predictors of the MBF responses to
adenosine or the CPT cannot be determined from this
study. However, the lack of differences in myocardial blood
flow between our type 1 (insulin deficient) and type 2
(hyperinsulinemic, insulin resistant) diabetics suggest that in
disease states including diabetes mellitus, insulin levels do
not appear to contribute significantly to coronary vasodila-
tion.
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Conclusions. The results of this study demonstrate mark-
edly reduced myocardial vasodilator reserve and sympathet-
ically mediated changes in MBF in subjects with both type
1 and type 2 diabetes. Importantly, the similarities in
coronary vascular dysfunction between the subjects with
type 1 and type 2 diabetes persisted after adjusting for
expected baseline differences in the duration of diabetes,
BMI, insulin treatment, lipid profile, and autonomic neu-
ropathy. Because patients with type 1 diabetes are insulin-
deficient (rather than insulin-resistant, the hallmark of type
2 diabetes), these results provide further support for a key
role of hyperglycemia in the pathogenesis of vascular dys-
function in diabetes.
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